Treatment Trials
Below is a listing by cancer type of the current treatment clinical trials for cancer offered through the Genesis Cancer Care Institute and Iowa Cancer Specialists. See clinical trials offered by Hematology-Oncology Associates of the Quad-Cities, PC.
Each trial below is linked to a complete description provided by the National Cancer Institute. You may then choose a patient version or health professional version to read and print out as you wish. If you need assistance with this process, contact us. You may search for other clinical trials through the following links: National Cancer Institute Clinical Trial Search; Emerging Med; Trial Check; or Center Watch.
Breast Cancer
NSABP B-39: A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) vs Partial Breast Irradiation (PBI) for Women With Stage 0, I or II Breast Cancer (Partial Closure)
NSABP B-43: A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women With HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy
NSABP B-47: A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel + Cyclophosphamide or Four Cycles of Doxorubicin + Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy + Trastuzumab in Women With Node-Positive or High Risk Node-Negative HER2-Low Invasive Breast Cancer
NSABP B-49: A Phase III Clinical Trial Comparing the Combination of Docetaxel plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
CTSU Wake Forest University (WFU) 97609: Impact of Genomics and Exposures on Disparities in Breast Cancer Radiosensitivity
SWOG S1007: A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER-2 Negative Breast Cancer (RS) of 25 or Less – Step 1 with Recurrence Score
SWOG S1105: Randomized Trial of Text-Messaging Intervention to Reduce Early Discontinuation of Adjuvant Aromatase Inhibitor Therapy in Women with Early Stage Breast Cancer
SWOG S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of EVEROLIMUS in Patients with High-Risk, Homone Receptor-Positive AND HER2/neu Negative Breast Cancer
back to top
Carcinoid Tumor
back to top
Gastro-Intestinal (Colon Cancer; Rectal Cancer; Gastrointestional Stromal Tumor)
CALGB/SWOG 80702: Phase III Trial of 6 versus 12 Treatments of Adjuvant FOLFOX plus Celecoxib or Placebo for Patients With Resected Stage III Colon Cancer
NSABP P-5: Statin Polyp Prevention Trial in Patients with Resected Colon Cancer
SWOG S1115: Randomized Phase II Clinical Trial of AZD6244 Hydrogen Sulfate (NSC-748727) and MK-2206 (NSC-749607) vs mFOLFOX in Patients with Metastatic Pancreatic Cancer After Prior Chemotherapy
SWOG S1201: A Randomized Phase II Pilot Study Prospectively Evaluating Treatment for Patients Based on ERCC1 (Excision Repair Cross-Complementing 1) for Advanced/Metastatic Esophageal, Gastric, or Gastroesophageal Junction (GEJ) Cancer
back to top
Genito-Urinary (Prostate; Kidney)
CALGB 90203: Randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy vs Immediate Radical Prostatectomy in Patients With High-Risk, Clinically Localized Prostate Cancer
SWOG S1014: Abiraterone Acetate Treatment for Prostate Cancer Patients with a PSA of More Than Four Following Initial Androgen Deprivation Therapy, Phase II
SWOG S0931: EVEREST--EVErolimus for Renal Cancer Ensuing Surgical Therapy, a Phase III Study
back to top
GYNECOLOGY (Endometrial; Ovarian Epithelial)
back to top
Head & Neck
back to top
Leukemia (Acute Myeloid (AML) Adult; Chronic Lymphocytic (CLL))
back to top
Lung (Non-Small Cell)
ECOG 1505: Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (> 4 cm)-IIIA Non-Small Cell Lung Cancer (NSCLC)
ECOG 5508: Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
CALGB 30801: A Randomized Phase III Double-Blind Trial Evaluating Selective COX-2 Inhibition in COX-2 Expressing Advanced Non-Small Cell Lung Cancer (NSCLC)
back to top
Lymphoma
back to top
Melanoma
back to top
Miscellaneous
SWOG S0702: Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients With Bone Metastases Starting Zoledronic Acid Treatment
back to top
Multiple Myeloma
ECOG E3A06: Randomized Phase III Trial of Lenalidomide vs Observation Alone in Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma
back to top
